OGA and Alzheimer disease: Little information exists in the published literature about the time course of the increase in O-GlcNAc in the hippocampus following systemic administration of OGA inhibitors, which is important given these drugs are being used in AD clinical trials (Bartolome-Nebreda et al., 2021; Selnick et al., 2019; Permanne et al., 2022).